Polysulfated Glycosaminoglycan

Verify with FDA CVM →

5,558 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
5,558
Total Reports
430
Deaths Reported
770.0%
Death Rate

Active Ingredients

Polysulfated Glycosaminoglycan

Administration Routes

UnknownSubcutaneousIntramuscularParenteralIntravenousIntra-ArticularOralTopicalOphthalmicIntradermal

Species Affected

Dog 3,834
Unknown 1,000
Horse 372
Cat 303
Human 27
Other Birds 7
Other 6
Rabbit 4
Duck 1
Starling 1

Most Affected Breeds

Unknown 1,136
Retriever - Labrador 704
Dog (unknown) 319
Shepherd Dog - German 279
Retriever - Golden 224
Domestic Shorthair 168
Dog (other) 99
Boxer (German Boxer) 94
Horse (unknown) 82
Chihuahua 80

Most Reported Reactions

Vomiting 1,033
Diarrhoea 743
Product Defect, General 653
Lack of efficacy - NOS 563
Lethargy (see also Central nervous system depression in 'Neurological') 530
Not eating 366
Color, Abnormal 267
Death by euthanasia 265
Other abnormal test result NOS 237
Elevated alanine aminotransferase (ALT) 234
Anorexia 229
Weight loss 223

Outcome Breakdown

Outcome Unknown
1,740 (38.2%)
Recovered/Normal
1,508 (33.1%)
Ongoing
848 (18.6%)
Euthanized
262 (5.7%)
Died
168 (3.7%)
Recovered with Sequela
33 (0.7%)

Data Summary

Metric Value
Total adverse event reports 5,558
Reports involving death 430
Case-fatality rate (reported events) 770.0%
Distinct species in reports 10
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Polysulfated Glycosaminoglycan Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 5,558 adverse event reports referencing Polysulfated Glycosaminoglycan, including 430 reports in which the animal died — a 770.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Polysulfated Glycosaminoglycan. Reported administration routes include Unknown, Subcutaneous, Intramuscular, Parenteral. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Polysulfated Glycosaminoglycan reports are Dog (3,834 reports), Unknown (1,000 reports), Horse (372 reports), with Dog accounting for the largest share. Within those species, Unknown (1,136), Retriever - Labrador (704), Dog (unknown) (319) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Polysulfated Glycosaminoglycan are Vomiting (1,033), Diarrhoea (743), Product Defect, General (653), Lack of efficacy - NOS (563). Of the 4,559 reports with a coded outcome, Outcome Unknown is the leading category at 38.2%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Polysulfated Glycosaminoglycan.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial